Did you know ubiquitously prescribed proton pump inhibitors (PPIs) negatively affect the oral bioavailability of CDK4/6-inhibitors? This South Korean analysis of claims data reports women receiving palbociclib for breast cancer had significantly reduced progression-free survival when concurrently on a PPI (n=344, median PFS 25 months) than when not (n=966, median PFS 40 months). | Lee, JAMA Netw Open 2023
